<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) during the course of Waldenstr√∂m's <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">macroglobulinemia</z:e> (WM) has been observed in rare patients </plain></SENT>
<SENT sid="1" pm="."><plain>In most of them, the condition developed after treatment with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We experienced a 65-year-old male patient who was diagnosed as WM </plain></SENT>
<SENT sid="3" pm="."><plain>He was treated with intermittent oral <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> for 12 months and three cycles of fludarabine, and complete response was achieved after fludarabine treatment </plain></SENT>
<SENT sid="4" pm="."><plain>During routine outpatient follow-up, severe <z:hpo ids='HP_0001903'>anemia</z:hpo> occurred </plain></SENT>
<SENT sid="5" pm="."><plain>His bone marrow aspirate showed dysplastic hemopoiesis with ringed sideroblasts and siderocytes, which is consistent with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>Cytogenetic analysis showed complex chromosomal abnormalities including 5q deletion, 12p deletion and <z:mp ids='MP_0004026'>monosomy</z:mp> 18 </plain></SENT>
<SENT sid="7" pm="."><plain>When decision is made to treat WM with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> and/or fludarabine, a potential risk for t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> should be considered and a close hematologic monitoring is needed </plain></SENT>
</text></document>